Search

Displaying results 2581 - 2590 of 9322 in total
  1. Drug

    CX-051869

    go.drugbank.com/drugs/DB31656
    Approved

    It is the active ingredient of the 2025-2026 formulation of Moderna's Spikevax vaccine.[L40074] … CX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1.

  2. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Therefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative

  3. Drug

    Benznidazole

    go.drugbank.com/drugs/DB11989
    ApprovedInvestigational

    [L939] It is the first treatment made available in the United States for Chagas disease. … Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.

  4. Drug

    Omapatrilat

    go.drugbank.com/drugs/DB00886
    Experimental

    This drug from BMS was not approved by the FDA due to angioedema safety concerns. … The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling.

    Categories: Agents Acting on the Renin-Angiotensin System
  5. Drug

    Glycerol phenylbutyrate

    go.drugbank.com/drugs/DB08909
    ApprovedInvestigational

    Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.

  6. Drug

    Temoporfin

    go.drugbank.com/drugs/DB11630
    Approved

    Temoporfin is a photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck [FDA Label]. … It was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.

  7. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    [L39332] It is currently under investigation for use in FRα-positive pituitary adenoma, lung cancer,[A242577] and renal-cell carcinoma, which is thought to be the second-highest folate receptor-expressing … [L39332] The longer wavelength allows for deeper penetration of the fluorescent light through tissues for better imaging and detection of tumours.

  8. Drug

    Strontium chloride

    go.drugbank.com/drugs/DB13987
    ApprovedWithdrawn

    Such strontium chloride toothpaste formulations may subsequently not be available for sale anymore in certain parts of the world [A33167, A33168]. … This kind of barrier protection for tooth hypersensitivity has, however, been superseded by other toothpaste formulations and ingredients designed to be nerve calming agents instead [A33167, A33168].

  9. Drug

    Hexachlorophene

    go.drugbank.com/drugs/DB00756
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)

    International brands: E-Z scrub
  10. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome